{"nctId":"NCT01596335","briefTitle":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","startDateStruct":{"date":"2012-05"},"conditions":["Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin"],"count":31,"armGroups":[{"label":"TA-650","type":"EXPERIMENTAL","interventionNames":["Drug: TA-650"]},{"label":"VGIH","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)"]}],"interventions":[{"name":"TA-650","otherNames":[]},{"name":"Polyethylene Glycol-treated Human Immunoglobulin (VGIH)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with Kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of Kawasaki disease.\n* Patients refractory to initial IVIG therapy (a single administration at 2 g per kg body weight).\n* Patients with a fever of 37.5ºC or higher axillary temperature at the time of enrollment.\n* Patients to whom the study drug can be administered by day 8 of disease.\n\nExclusion Criteria:\n\n* Patients who have received vaccination with Bacille Calmette-Guérin (BCG) vaccine within 6 months before the enrollment.\n* Patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization.\n* Patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections.\n* Patients complicated with active tuberculosis, active hepatitis B or C, or patients confirmed to be hepatitis B virus carriers or a history of hepatitis B.\n* Patients confirmed to have HIV infection, or patients with a family history of HIV infection.\n* Patients who have a history of receiving treatment with infliximab or other biological products.\n* Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Fever","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.00","spread":null},{"groupId":"OG001","value":"42.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.90","spread":null},{"groupId":"OG001","value":"25.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Coronary Artery Lesions","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Double stranded DNA antibody positive","Epistaxis","Nasopharyngitis","Upper respiratory tract inflammation","Constipation"]}}}